Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
The lawsuit accused Bristol Myers of depriving holders of "contingent value rights" (CVR) an extra $9 per share in cash by ...
Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...
Kennedy Jr. has been a vocal critic of the pharma industry. He’s said it’s corrupted U.S. health agencies and has attacked, ...
Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb Company - Preferred ...
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb (NYSE:BMY) with a Peer ...
Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...
NEW YORK (Reuters) - Bristol Myers Squibb (BMY) was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs ...
Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.
Following US President-elect Donald Trump's announcement that Robert F Kennedy (RFK) Jr will be appointed as head of the ...